It is crucial to improve diversity, equity, and inclusion (DEI) in clinical trials for the health and well-being of everyone.
While oncology has been slower to adopt decentralized clinical trials than other medical specialties, many oncologists realize this type of service could be a game-changer for cancer research and treatments.
Though vaccine developers rapidly adopted decentralized clinical trials during the pandemic, today there is a surprisingly slow uptake of novel technologies across vaccine studies compared to other therapy areas.
There is a real human need contingent upon clinical trials meeting their targeted enrollment, retaining participants, attaining crucial milestones, and resulting in successful outcomes.
With biologics dominating headlines, one might be tempted to think that small molecule discovery is fading, or that there is little viable target and drug space left uncovered. This simply isn’t the case.